First Allied Advisory Services’s Jazz Pharmaceuticals JAZZ Stock Holding History

First Allied Advisory Services’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,757	Closed	-$260K	–	1152
2019 Q4	$260K	Sell	1,757 -737	-30%	-$100K	0.01%	1003
2019 Q3	$318K	Sell	2,494 -739	-23%	-$99.1K	0.01%	872
2019 Q2	$461K	Sell	3,233 -329	-9%	-$44.2K	0.02%	709
2019 Q1	$510K	Buy	3,562 +520	+17%	+$67.8K	0.02%	670
2018 Q4	$374K	Sell	3,042 -9,643	-76%	-$1.43M	0.01%	703
2018 Q3	$2.13M	Sell	12,685 -4,226	-25%	-$727K	0.07%	284
2018 Q2	$2.91M	Sell	16,911 -2,052	-11%	-$335K	0.11%	212
2018 Q1	$2.86M	Buy	+18,963	New	+$2.78M	0.11%	211
2016 Q4	–	Sell	-10,004	Closed	-$1.22M	–	1136
2016 Q3	$1.22M	Buy	10,004 +2,178	+28%	+$294K	0.06%	317
2016 Q2	$1.11M	Buy	7,826 +22	+0.3%	+$3.24K	0.06%	321
2016 Q1	$1.02M	Sell	7,804 -270	-3%	-$33.6K	0.06%	335
2015 Q4	$1.14M	Buy	+8,074	New	+$1.12M	0.06%	339

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

First Allied Advisory Services's JAZZ Position: Q1 2020 in Review

First Allied Advisory Services sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2020, closing a stake of 1,757 shares — an estimated $260K sold.

First Allied Advisory Services first reported a position in JAZZ in Q4 2015 and held it in 12 quarters. The position peaked at $2.91M in Q2 2018. 407 funds tracked by Wall St. Rank hold JAZZ as of Q1 2020.

First Allied Advisory Services reported no remaining Jazz Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
First Allied Advisory Services sold 1,757 Jazz Pharmaceuticals shares in Q1 2020, an estimated $260K.
First Allied Advisory Services first reported a position in Jazz Pharmaceuticals in Q4 2015 and held it in 12 quarters.
First Allied Advisory Services's Jazz Pharmaceuticals position peaked at $2.91M in Q2 2018.
407 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2020.

Based on First Allied Advisory Services's 13F filing for Q1 2020, filed 8 May 2020.